ICLE 2022 | A novel humanized mouse model for the study of cell therapies
Juliane Mietz, University Of Zurich, Zurich, Switzerland, gives an overview of developing a novel tumor model to study immunotherapies using humanized mice with an endogenous immune system. Hematopoietic progenitor cells (HPCs) sourced from fetal liver tissue generated an endogenous immune system and tumor tissue derived from donor B-cells infected with the Epstein-Barr virus (EBV) created an immortalized lymphoblastoid cell line (LCL). Insertion of the LCL in the mice resulted in tumor growth and subsequent regression, demonstrating an immunocompetent mouse model. Function assays additionally revealed the tumors to express more activation markers such as CD39 and CD69. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.
